Premium
Incidental prostate cancer at radical cystoprostatectomy: implications for apex‐sparing surgery
Author(s) -
Gakis Georgios,
Schilling David,
Bedke Jens,
Sievert Karl D.,
Stenzl Arnulf
Publication year - 2010
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2009.08739.x
Subject(s) - medicine , prostate cancer , urology , prostate , rectal examination , cystoprostatectomy , cancer , urinary continence , prostatectomy
Study Type – Therapy (case series)
Level of Evidence 4 OBJECTIVE To analyse retrospectively the clinicopathological features of incidental prostate cancer in patients undergoing radical cystoprostatovesiculectomy (RCP) for invasive bladder cancer, as recent studies suggest that prostatic apex‐sparing surgery in patients undergoing RCP improves urinary continence and erectile function after surgery, but in those with incidental prostate cancer, leaving the apical region endangers the oncological outcome. PATIENTS AND METHODS From 2004 to 2007, at our institution, 95 men had RCP for invasive bladder cancer. We reviewed their clinicopathological variables, especially apical involvement, and the course of prostate‐specific antigen (PSA) levels before and after surgery. We compared clinically significant and insignificant prostate cancers. RESULTS Of the 95 patients, 26 had incidental prostate cancer (mean age 68 years, range 53–80) on definitive histological examination. The mean ( sd , range) preoperative PSA level in all 26 men was 3.6 (0.8, 0.2–14) ng/mL, but six of the 26 patients had preoperative PSA levels of >4 ng/mL and one other had suspicious findings on a digital rectal examination. Involvement of the apex was histologically confirmed in seven of the 26 patients (27%), including four with significant prostate cancer ( P = 0.039). Preoperative PSA levels did not differ significantly between the seven patients with significant and 19 with insignificant prostate cancer, but seven patients with apical involvement had significantly higher PSA levels before RCP than the 19 who did not ( P < 0.04). PSA levels after RCP remained below the limit of detection in all patients over a mean (range) follow‐up 14.3 (3–32) months. CONCLUSION In our series, preserving the apex of the prostate to decrease morbidity after RCP carried a 7.3% risk (seven of 95 patients) of leaving significant cancer in the residual prostatic tissue. No preoperative clinical value could exclude apical involvement. Therefore, our findings stress the oncological need for a careful and complete excision of the prostate during RCP.